Welcome to LookChem.com Sign In|Join Free

CAS

  • or

26820-38-2

Post Buying Request

26820-38-2 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

26820-38-2 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 26820-38-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,6,8,2 and 0 respectively; the second part has 2 digits, 3 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 26820-38:
(7*2)+(6*6)+(5*8)+(4*2)+(3*0)+(2*3)+(1*8)=112
112 % 10 = 2
So 26820-38-2 is a valid CAS Registry Number.

26820-38-2SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name N-methyl-3,5-dinitropyridin-4-amine

1.2 Other means of identification

Product number -
Other names 3,5-Dinitro-4-methylaminopyridin

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:26820-38-2 SDS

26820-38-2Downstream Products

26820-38-2Relevant articles and documents

Novel tricyclic inhibitors of 1κB kinase

Kempson, James,Spergel, Steven H.,Guo, Junqing,Quesnelle, Claude,Gill, Patrice,Belanger, Dominique,Dyckman, Alaric J.,Li, Tianle,Watterson, Scott H.,Langevine, Charles M.,Das, Jagabandhu,Moquin, Robert V.,Furch, Joseph A.,Marinier, Anne,Dodier, Marco,Martel, Alain,Nirschl, David,Van Kirk, Katy,Burke, James R.,Pattoli, Mark A.,Gillooly, Kathleen,McIntyre, Kim W.,Laishun, Chen,Zheng, Yang,Marathe, Punit H.,Wang-Iverson, David,Dodd, John H.,McKinnon, Murray,Barrish, Joel C.,Pitts, William J.

experimental part, p. 1994 - 2005 (2009/12/31)

The design and synthesis of a novel series of oxazole-, thiazole-, and imidazole-based inhibitors of IκB kinase (IKK) are reported. Biological activity was improved compared to the pyrazolopurine lead, and the expedient synthesis of the new tricyclic systems allowed for efficient exploration of structure-activity relationships. This, combined with an iterative rat cassette dosing strategy, was used to identify compounds with improved pharmacokinetic (PK) profiles to advance for in vivo evaluation.

8H-IMIDAZO[4,5-D]THIAZOLO[4,5-B]PYRIDINE BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME

-

Page/Page column 55-56, (2008/06/13)

The present invention provides for thiazolopyridine-based tricyclic compounds having the formula (I) wherein R1, R2, R5 and R6 are as described herein. The present invention further provides pharmaceutical compo

Imidazo-fused oxazolo[4,5-b]pyridine and imidazo-fused thiazolo[4,5-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same

-

Page/Page column 23, (2010/11/30)

The present invention provides for pyrazolopurine-based tricyclic compounds having the formula (I), wherein R1, R2, R3, and R6 are as described herein. The present invention further provides pharmaceutical compositions comprising such compounds, as well as the use of such compounds for treating inflammatory and immune diseases.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 26820-38-2